|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research Article |
Follicle Biology Laboratory,3 Free University of Brussels, 1090 Brussels, Belgium
Fertility and IVF Unit,4 Assaf Harofeh Medical Center-Tel Aviv University, Tel Aviv 70300, Israel
ABSTRACT
Controlling nuclear maturation during oocyte culture might improve nuclear-cytoplasmic maturation synchrony. We aimed to evaluate the quality of in vitro-matured, germinal vesicle (GV)-stage human oocytes following a prematuration culture (PMC) with a meiotic arrester, phosphodiesterase 3-inhibitor (PDE3-I). Follicles (diameter, 612 mm) were retrieved 3436 h post-hCG administration from informed, consenting patients who had undergone controlled ovarian stimulation. Cumulus-enclosed oocytes (CEOs) presenting moderate expansion or full compaction were placed in PMC with the PDE3-I, Org9935, for 24 or 48 h. Subsequently, oocytes were removed from PMC, denuded of cumulus cells, matured in vitro, and fertilized, and the resulting embryos were cultured. In the presence of PDE3-I, approximately 98% of the oocytes were arrested at the GV stage. Following PDE3-I removal, oocytes acquired a higher maturation rate than oocytes that were immediately denuded of cumulus cells after retrieval and in vitro matured (67% vs. 46%, P = 0.01). In controls, immature CEOs retrieved with moderate expansion reached higher maturation rates compared to fully compacted CEOs, but in PMC groups, high values of maturation were achieved for both morphological classes of CEOs. No effect of PMC on fertilization was observed. A 24-h PMC period proved to be the most effective in preserving embryonic integrity. Similar proportions of nuclear abnormalities were observed in embryos of all in vitro groups. In summary, PMC with the specific PDE3-I had a beneficial effect on human CEOs by enhancing maturation, benefiting mainly the fully compacted CEOs. This resulted in an increased yield of mature oocytes available for insemination without compromising embryonic development. These results suggest that applying an inhibitor to control the rate of nuclear maturity by regulating intraoocyte PDE3 activity may allow the synchronization of nuclear and ooplasmic maturation.
cumulus cells, cyclic adenosine monophosphate, gamete biology, oocyte development, phosphodiesterases
1 Supported in part by grants from Novo Nordisk A/S.
2 Correspondence: D. Nogueira, Follicle Biology Laboratory, Free University of Brussels (Vrije Universiteit Brussel), Laarbeeklaan, 101, Brussels 1090, Belgium. FAX: 32 2 477 50 60; daniela_nogueira{at}yahoo.com
This article has been cited by other articles:
![]() |
I. Segers, T. Adriaenssens, W. Coucke, R. Cortvrindt, and J. Smitz Timing of Nuclear Maturation and Postovulatory Aging in Oocytes of In Vitro-Grown Mouse Follicles with or Without Oil Overlay Biol Reprod, May 1, 2008; 78(5): 859 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-m. Shu, H.-t. Zeng, Z. Ren, G.-l. Zhuang, X.-y. Liang, H.-w. Shen, S.-z. Yao, P.-q. Ke, and N.-n. Wang Effects of cilostamide and forskolin on the meiotic resumption and embryonic development of immature human oocytes Hum. Reprod., March 1, 2008; 23(3): 504 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-T. Wu, L. Tang, J. Cai, X.-E Lu, J. Xu, X.-M. Zhu, Q. Luo, and H.-F. Huang High bone morphogenetic protein-15 level in follicular fluid is associated with high quality oocyte and subsequent embryonic development Hum. Reprod., June 1, 2007; 22(6): 1526 - 1531. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Russell and R. L. Robker Molecular mechanisms of ovulation: co-ordination through the cumulus complex Hum. Reprod. Update, May 1, 2007; 13(3): 289 - 312. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Vanhoutte, P. De Sutter, D. Nogueira, J. Gerris, M. Dhont, and J. Van der Elst Nuclear and cytoplasmic maturation of in vitro matured human oocytes after temporary nuclear arrest by phosphodiesterase 3-inhibitor Hum. Reprod., May 1, 2007; 22(5): 1239 - 1246. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |